Navarro M, Bellmunt J, Balañá C, Colomer R, Jolis L, del Campo J M
Department of Radiotherapy and Oncology, Valle Hebron Hospital, Barcelona, Spain.
Oncology. 1989;46(3):137-42. doi: 10.1159/000226702.
Forty-two patients with metastatic breast cancer refractory to first-line therapies were treated with combination chemotherapy with mitomycin-C and vinblastine. A response to treatment was observed in 11 of 34 evaluable patients (32.3%), with 3 complete remissions (8.8%) and 8 partial remissions (23.5%). The median duration of response was 185+ days. The 12-month survival was 78% for responders, 48% for patients with stable disease and 0% for patients with progressive disease. The toxicity was acceptable with 20 episodes of moderate myelosuppression (58.8%) and 2 cases with congestive heart failure that responded to medical treatment. The MMC-VBL combination is an active regime for advanced breast cancer previously treated with antracyclines. This combination may be regarded as a standard second-line treatment for this type of tumor.
42例一线治疗难治的转移性乳腺癌患者接受了丝裂霉素-C和长春碱联合化疗。34例可评估患者中有11例（32.3%）观察到治疗反应，其中3例完全缓解（8.8%），8例部分缓解（23.5%）。反应的中位持续时间为185 +天。反应者的12个月生存率为78%，病情稳定患者为48%，病情进展患者为0%。毒性可以接受，有20例中度骨髓抑制（58.8%），2例充血性心力衰竭经药物治疗有效。MMC-VBL联合方案对先前接受过蒽环类药物治疗的晚期乳腺癌是一种有效的治疗方案。该联合方案可被视为这类肿瘤的标准二线治疗方案。
